Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Due to their lipid solubility, general anesthetic agents rapidly cross the blood–brain barrier and the placenta. In addition to their sleep-inducing effect in the brain, they also frequently have a depressant effect on the respiratory center. Thus, during the perinatal phase, there is a risk of hypoxia from neonatal respiratory depression. Fortunately there is no indication that an uncomplicated general anesthetic can lead to developmental disorders. Based on our current knowledge, the commonly used injection or inhalation anesthetics do not have teratogenic properties. However, impairments of respiration and circulation arising in the course of maternal anesthesia, stronger uterine contractions or events such as malignant hyperthermia can also harm the fetus.
Although there are only limited epidemiological data on individual anesthetics, the effects of surgery under anesthesia on pregnant women have been examined in some larger studies. When various anesthetics were combined, none of these older studies found significant indications of damaging effects ( ). In animal experiments, some anesthetic agents have shown neurotoxic effects on the developing brain ( ), possibly through interaction at the glutamate N -methyl- d -aspartate (NMDA) receptor. Substantial debate continues as to whether these animal results are applicable to humans, because in humans, the exposure are generally a single anesthetic and are usually of shorter duration in relation to brain development than in these animal experiments ( ). The results from studies conducted in young children, mostly retrospective to date, are not uniform. It is difficult to control for confounders like pre-existing diseases which might contribute to the incidence of repeat operations ( ). Large prospective multicenter studies are currently being conducted to clarify these questions, e.g. the PANDA study (Pediatric Anesthesia and Neurodevelopment Assessment, www.kidspandastudy.org ) or the GAS study (compare also http://www.smarttots.org/research/relatedstudies.html ). Results are not expected before 2015.
Local anesthetics that are either injected or sprayed on tissue were long considered the agents of choice during pregnancy because it was assumed that the anesthetics remain at the site of administration and so would not pass to the fetus. However, even with this form of anesthesia, complications cannot be ruled out since local anesthetics also reach the fetus following adsorption into the mother’s circulation, depending on the location and vascularization at the injection site ( ).
Muscle relaxants used in connection with surgical procedures are quaternary ammonia salts which, under physiological conditions, are available in a highly ionized form and therefore pass through the placenta only relatively slowly. Nevertheless, they reach the fetus in detectable amounts. Overall, no differences were found in the Apgar scores or the postpartum neurological adaptation of the newborns after caesarean section regardless of whether the mother had had general anesthesia with desflurane or sevoflurane or epidural anesthesia ( ).
Desflurane , enflurane , halothane , isoflurane and sevoflurane are halogenated inhalation agents. In the perinatal phase, attention should be paid to their relaxant effect on the uterus, which can lead to a reduction in contraction activity with increased risk of bleeding and to their respiratory depressant effect, especially with high risk births. The uterine relaxing effect is used for example during ex utero intrapartum treatment (EXIT procedure) to resuscitate a fetus with a difficult airway on placental support or in fetal surgery in order to carry out operations on the baby in the opened uterus ( ). Even with uncomplicated caesarean section, uterine atony can lead to increased loss of blood, in this context the relaxant effect of the inhalation agents is unwanted. The rapid dispersal of the newer inhalation anesthetics (sevoflurane, desflurane) leads to a more rapid normalization of the uterine tone after the operation is finished ( ).
Of all the anesthetic agents, desflurane has the lowest blood/gas and tissue/blood distribution coefficients, as well as the least solubility. It is the weakest effective halogenated anesthetic gas. Desflurane is, like isoflurane, only minimally metabolized, so the toxic potential is low. Because of rapid induction and wake-up times, desflurane is frequently used for anesthesia for caesarean section with no known disadvantages for the newborn or the mother. No teratogenic effects in humans are known. Similar to the other halogenated inhalation anesthetics, the uterine relaxing effect is dependent on the depth of anesthesia and its strength is similar to that of halothane ( ). Because of rapid diffusion and dispersal, however, the uterine tone is more easily regulated.
Enflurane is a fluorinated ether, which is only 2–5% metabolized. The use in Caesarean anesthesia is well-tolerated by newborns ( ). No teratogenic effects are known among humans. Due to the less favorable properties of enflurane in comparison to isoflurane it is now only rarely used for anesthesia.
Halothane is one of the oldest and most widely used of the halogenated inhalation anesthetics. There are no known teratogenic effects in humans. In animal studies, however, skeletal and other anomalies, fetal growth retardation, behavioral anomalies and death of the offspring have been found. These anomalies have not been observed in humans with normal use. When halothane is given at delivery (i.e. for caesarean section) there may be more pronounced uterine atony with an increased risk of bleeding as well as respiratory depression in the newborn. Among the inhalation anesthetics, halothane has the strongest circulatory depressive effect. High doses can cause cardiac arrythmias and cardiac arrest in the mother, especially with the use of β-sympathomimetic tocolytics or catecholamines. Halothane has the highest rate of metabolization (15–20%, mainly in the liver) of the inhalation anesthetics now still in use. There have been reports of liver toxicity after repeat anesthesia. Therefore it is mostly replaced by the newer agents (desflurane, sevoflurane) today.
Isoflurane is a structural isomer of enflurane. With a metabolization rate of only 0.2%, it belongs, like desflurane, to the halogenated inhalation anesthetics that are only minimally metabolized. In the course of in vitro fertilization under isoflurane anesthesia, no reduced implantation rate was seen ( ). Anesthesia with isoflurane for a caesarean delivery is well-tolerated by the fetus. A slight increase in neonatal bilirubin values has been discussed ( ). No teratogenic effects among humans are known.
Sevoflurane has only fluoride as a halogen. The wash-in rate is somewhat slower than that of desflurane, but faster than that of all the other halogenated inhalation anesthetics. The metabolization rate is between 3 and 5%. It is used in many obstetrical centers today as the standard inhalation anesthetic for caesarean section with no known negative effects on the newborn. No teratogenic risks are known in humans. The uterine relaxing effect of sevoflurane is similar to that of halothane or desflurane and, due to the rapid diffusion and dispersal, just as easily regulated as with the use of desflurane ( ).
Halogenated anesthetics are among the standard anesthetic agents used in obstetrics. Being aware of the characteristic side-effects, they can be used at any time during the entire pregnancy. When used during labor, uterine relaxation and the related risk of hemorrhage and depressive effects on the newborn need to be kept in mind.
Ether (ether as anesthetic agent) has only historical significance today. Because of serious side-effects such as, for instance, the explosiveness of an ether-air mix, post-operative nausea and vomiting and agitation, ether is no longer used as an anesthetic in most industrialized countries. Ether reaches the fetus unimpeded. There are no indications of teratogenic properties in humans.
Ether drip anesthesia is not indicated during pregnancy or in obstetrics. Due to serious side effects it should only be used in a setting when no other anesthetic possibility is available.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here